Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

The Lancet. Oncology - 1 Feb 2003

Gambacorti-Passerini Carlo B, Gunby Rosalind H, Piazza Rocco, Galietta Annamaria, Rostagno Roberta, Scapozza Leonardo

Abstract excerpt

Imatinib (STI571 or CGP57148B) is an innovative treatment for tumours with a constitutively activated form of c-ABL, c-KIT, or PDGFR. Such tumours include Philadelphia-chromosome-positive (Ph-positive) leukaemias, gastrointestinal stromal tumours, and PDGFR-positive leukaemias. Diseases such as primary hypereosinophilia and dermatofibrosarcoma protuberans also seem to respond to imatinib. Clinical trials...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Acute Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Fusion Proteins, bcr-abl

Share to Gene Amplification

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Source

Identifiers

PMID: 12573349
DOI: 10.1016/s1470-2045(03)00979-3

Genes

BCR
KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.PMID 12573349Read ↗

Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia.Semantic proximity Read ↗

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.Semantic proximity Read ↗

Clinical resistance to imatinib: mechanisms and implications.Semantic proximity Read ↗

Treating imatinib-resistant leukemia: the next generation targeted therapies.Semantic proximity Read ↗

Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.Semantic proximity Read ↗

Molecular mechanisms of resistance to STI571 in chronic myeloid leukemiaSemantic proximity Read ↗

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.Semantic proximity Read ↗

Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistanceSemantic proximity Read ↗

Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes backSemantic proximity Read ↗

New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib ResistanceSemantic proximity Read ↗

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.Semantic proximity Read ↗

Resistance to imatinib in chronic myelogenous leukemia: mechanisms and clinical implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.